10-K: CNS Pharmaceuticals Reports 2024 Results, Focuses on TPI 287 Development After Berubicin Trial Outcome

Sentiment:

Annual Results 31 March 2025 5:11 PM

📋All filings for Cns Pharmaceuticals, INC

CNS Pharmaceuticals' 10-K filing reveals a year of strategic shifts, focusing on TPI 287 development and analyzing the path forward after topline data from the Berubicin trial did not meet its primary endpoint.

Capital raiseThe company anticipates needing to raise additional financing through the sale of equity or debt securities.The company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.

Worse than expectedThe Berubicin Phase 2 trial did not meet its primary endpoint of statistically significant overall survival compared to Lomustine in GBM patients.

Summary

CNS Pharmaceuticals, Inc. filed its 10-K report for the fiscal year ended December 31, 2024.
The company is focused on developing anti-cancer drug candidates for brain and central nervous system tumors, primarily TPI 287 and Berubicin.
Topline data from a Berubicin clinical trial for Glioblastoma Multiforme (GBM) did not demonstrate a statistically significant difference in overall survival compared to Lomustine.
The company is evaluating potential paths forward for Berubicin in consultation with the FDA.
CNS Pharmaceuticals acquired an exclusive license to intellectual property rights related to TPI 287 in the United States, Canada, Mexico, and Japan.
The company estimates it has sufficient capital to take it into the first quarter of 2026, during which it expects to initiate a trial of TPI 287 and complete the Berubicin trial analysis.
The company anticipates needing to raise additional financing through the sale of equity or debt securities.
The net loss for the year ended December 31, 2024, was approximately $14.86 million, compared to $18.85 million for 2023.
As of December 31, 2024, the company had cash of approximately $6.46 million and working capital of approximately $6.13 million.
The company's independent auditor expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is progressing with TPI 287 and has sufficient funds for the near term, the Berubicin trial results and the auditor's going concern warning raise significant concerns.

Positives

CNS Pharmaceuticals secured an exclusive license for TPI 287, potentially expanding its treatment options for CNS cancers.
The company has sufficient capital to fund operations into the first quarter of 2026.
The net loss decreased from $18.85 million in 2023 to $14.86 million in 2024.
The company has $6.46 million in cash and cash equivalents as of December 31, 2024.
The company has working capital of approximately $6.13 million as of December 31, 2024.

Negatives

The Berubicin Phase 2 trial did not meet its primary endpoint, raising questions about its future development.
The company's auditor expressed substantial doubt about its ability to continue as a going concern.
The company has a history of net losses and negative cash flows.
The company will likely need to raise additional capital through the sale of equity or debt securities.
The company terminated the HPI License on March 23, 2025.

Risks

The company's success depends on the successful development and commercialization of TPI 287 and Berubicin.
Delays in clinical trials could increase costs and delay regulatory approval.
The company may not be able to obtain regulatory approval for TPI 287 and Berubicin.
The company faces competition from other biotechnology and pharmaceutical companies.
The company may not be able to attract and retain key personnel.
The company may be materially adversely affected in the event of cyber-based attacks, network security breaches, service interruptions, or data corruption.
The company may be required to repurchase certain of its warrants upon a fundamental transaction, which may prevent or deter a third party from acquiring us.
The company has been unable to maintain compliance with the listing requirements of The Nasdaq Capital Market, and any future failure to maintain compliance could subject our common stock to be delisted from The Nasdaq Capital Market, which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.

Future Outlook

The company plans to focus on the clinical trial for TPI 287 and complete the ongoing trial of Berubicin, estimating sufficient capital to take it into the first quarter of 2026. Additional financing will likely be required through the sale of equity or debt securities.

Management Comments

Management believes that the cash on hand, combined with aggressive working capital management, will allow us to continue operating Within one year after the date that the financial statements are issued.

Industry Context

CNS Pharmaceuticals operates in a highly competitive segment of the pharmaceutical market, facing competition from numerous sources including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. The unmet medical need for more effective cancer therapies is such that oncology drugs are one of the leading class of drugs in development.

Comparison to Industry Standards

The current standard for the initial treatment of glioblastoma is surgery, followed by radiation in combination with TMZ, followed by maintenance TMZ.
Treatment with Lomustine is considered to be the standard of care for recurrent glioblastoma even though it is not formally approved by the FDA for this purpose, a fact which highlights the lack of available options for treatment.
While the percentage of patients who survive two years from the diagnosis of glioblastoma has increased because of the use of TMZ, overall survival for GBM patients remains dismal.
There are currently at least 77 different experimental therapies under clinical development in the United States for recurrent GBM based on the clinicaltrials.gov website.

Stakeholder Impact

Shareholders face uncertainty due to the Berubicin trial outcome and the company's need for additional financing.
Employees may experience uncertainty due to the company's financial situation and potential strategic shifts.
Patients may have limited access to new treatment options if Berubicin development is halted.

Next Steps

Evaluate potential paths forward for Berubicin in consultation with the FDA.
Initiate a clinical trial for TPI 287.
Raise additional financing through the sale of equity or debt securities.

Key Dates

Date	Description
2017-07-27	CNS Pharmaceuticals, Inc. organized as a Nevada corporation.
2017-11-21	Entered into Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc.
2017-12-28	Obtained rights to a worldwide, exclusive royalty-bearing license to Berubicin from HPI.
2019-11-13	Closed its IPO, completing the acquisition of intellectual property discussed in the HPI agreement.
2020-06-10	FDA granted Orphan Drug Designation for Berubicin for the treatment of malignant gliomas.
2020-12-17	Announced that IND application with the FDA for Berubicin for the treatment of Glioblastoma Multiforme was in effect.
2021-07-24	Received Fast Track Designation from the FDA for Berubicin.
2024-01-29	Entered into a placement agency agreement with A.G.P./Alliance Global Partners (AGP) and Maxim Group LLC (Maxim and collectively with AGP, the Placement Agents) (the Placement Agreement) for the public offering by the Company of (i) 889 shares (the Shares) of the Companys common stock, par value $0.001 per share (the Common Stock) (ii) pre-funded warrants to purchase 4,448 shares of Common Stock (the Pre-Funded Warrants); (iii) Series A Warrants to purchase up to an aggregate of 5,342 shares of Common Stock (the Series A Warrants); and (iv) Series B Warrants to purchase up to an aggregate of 5,342 shares of Common Stock (the Series B Warrants, and together with the Series A Warrants, the Common Warrants)).
2024-02-01	The closing of the sales of these securities occurred on February 1, 2024. The net proceeds to the Company from the offering were $ 3,331,000 , after deducting the placement agents fees and other offering expenses.
2024-04-30	Stockholders approved an amendment to the Companys amended and restated articles of incorporation (the Amendment) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50.
2024-06-04	The reverse stock split became effective on June 4, 2024 on a 1-for-50 basis without any change in the par value per share, which remained at $0.001.
2024-06-14	Entered into securities purchase agreements with institutional investors for the sale by the Company of 6,720 shares of the Companys common stock and pre-funded warrants to purchase 601 shares of common stock in lieu thereof in a registered direct offering.
2024-06-26	Entered into securities purchase agreements with institutional investors for the sale by the Company of 11,360 shares of the Companys common stock in a registered direct offering.
2024-07-03	Entered into securities purchase agreements with institutional investors for the sale by the Company of 28,500 shares of the Companys common stock in a registered direct offering.
2024-07-26	Entered into a Sales Agreement (the AGP ATM Sales Agreement) with A.G.P./Alliance Global Partners (AGP).
2024-07-29	Entered into an Exclusive License Agreement and Stock Purchase Agreement with Cortice Biosciences, Inc.
2024-10-23	Entered into securities purchase agreements with institutional investors for the sale by the Company of 74,000 shares of the Companys common stock in a registered direct offering.
2024-11-26	Stockholders of the Company approved an amendment to the Companys amended and restated articles of incorporation (the Amendment) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50.
2025-02-21	The reverse stock split became effective on February 21, 2025 on a 1-for-50 basis without any change in the par value per share, which remained at $0.001.
2025-03-23	The Company terminated the HPI License.
2025-03-25	CNS released topline data from a primary analysis of a clinical trial being conducted to evaluate the efficacy of Berubicin in patients with Glioblastoma Multiforme who have failed primary treatment for their disease.

Keywords

TPI 287, Berubicin, Glioblastoma, Clinical Trials, FDA, Orphan Drug Designation, CNS Pharmaceuticals, Drug Development, Oncology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.